Elan (ELN +1.1%) trades higher this morning after UBS ups the shares to Buy, citing the spin-off...

Elan (ELN +1.1%) trades higher this morning after UBS ups the shares to Buy, citing the spin-off of its Discovery Science and Neotope Biosciences businesses. The firm says the move turns it into a Tysabri-focused company with significant growth and under-appreciated operating leverage. Additionally, S&P put the stock's rating on creditwatch with positive implications, saying the spinoff is likely to lead to a better risk profile.

Comments (1)
  • 1ralphlabr
    , contributor
    Comments (5) | Send Message
    Contrary to the conservative opinion the "Affordable Health Care Act AKA ObamaCare is going to be a financial windfall for the medical/Biotech industry. companies eg. Elan are in the vangard of this explosion in medician and the cures to come. Although there are other industries that I reseach, my principal focus is in biotech and eg. gene technology. You have to ask yourself if there wasn't a human/public good for the Affordable Care legislation why did the Supreme court turned back all of this conservative gibberish? As we come forward with new technologies and products our public cost for health will deminish.
    14 Aug 2012, 03:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs